其他
岩藻糖敲除宿主细胞株(CHO-K1-TGZ)在抗体药物生产的应用
抗体抗肿瘤药物
发挥作用的基本机理
参考资料:
1,药渡数据库.2,Nitin Agarwal etal; N-Glycosylation of IgG and IgG-Like Recombinant Therapeutic Proteins: Why Is It Important and How Can We Control It? ; Annu. Rev. Chem. Biomol. Eng. 2020. 11:13.1-13.28.3,药融云数据;最高涨237% | 抗肿瘤药销售Top10公布(附名单).4,Lewis, G. D. et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37, 255-263 (1993).5,Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26, 1789-1796, doi:10.1200/JCO.2007.14.8957 (2008).6,Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754-758 (2002).7,Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21, 3940-3947, doi:10.1200/JCO.2003.05.013 (2003).8,Anolik, J. H. et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48, 455-459, doi:10.1002/art.10764 (2003).9,Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. The Journal of biological chemistry 278, 3466-3473, doi:10.1074/jbc.M210665200 (2003).10,Shibata-Koyama, M. et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Experimental hematology 37, 309-321, doi:10.1016/j.exphem.2008.11.006 (2009).11,Junttila, T. T. et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer research 70, 4481-4489, doi:10.1158/0008-5472.CAN-09-3704 (2010).12,Oppenheim, D. E. et al. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. British journal of cancer 110, 1221-1227, doi:10.1038/bjc.2014.35 (2014).13,Beck, A. & Reichert, J. M. Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs 4, 419-425, doi:10.4161/mabs.20996 (2012).14,Satoh, M., Iida, S. & Shitara, K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert opinion on biological therapy 6, 1161-1173, doi:10.1517/14712598.6.11.1161 (2006).研发投入居国内TOP3,四处出击的复星医药野心不止于医药……
点击"阅读原文",随时掌握行业动态